Pan-Canadian overpricing of medicines: a 6-country study of cost control for generic medicines.

Reed F Beall, Jason W Nickerson, Amir Attaran

Abstract read

In one paragraph

Article in Open medicine : a peer-reviewed, independent, open-access journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it

0cells of the map it votes in

7citing papers in PubMed, 2 pooled it

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

Implementation of medicines pricing policies in sub-Saharan Africa: systematic review.Systematic reviews · 2022
Pooled it
Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.PloS one · 2017
Pooled it
Canadian list of essential medications: Potential and uncertainties.Canadian family physician Medecin de famille canadien · 2017
Article
Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2017
Article
Universal prescription drug coverage in Canada: Long-promised yet undelivered.Healthcare management forum · 2016
Review
A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada.Healthcare policy = Politiques de sante · 2016
Article
Bias within economic evaluations - the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug.ClinicoEconomics and outcomes research : CEOR · 2015
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Reed F BeallReed F. Beall, MA, is a PhD candidate in the Institute of Population Health at the University of Ottawa, Ottawa, Ontario.

Jason W NickersonJason W. Nickerson, RRT, PhD, is a Clinical Investigator at the Bruyère Research Institute, Ottawa, Ontario.

Amir AttaranAmir Attaran, DPhil, LLB, is Associate Professor and Canada Research Chair in Law, Population Health and Global Development Policy at the University of Ottawa, Ottawa, Ontario.

Funding

Canadian Institutes of Health Research

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CanadaCost ControlCosts and Cost AnalysisDrugs, GenericGlobal HealthHumansDrugs, Generic

Identifiers

PMID25426181

PMCPMC4242790

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.